Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.67 |
| ▸ | CASR | P41180 | 4/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26804134 | 0.92 | SLC6A3 (0.78) | SLC6A3CASRFOLH1ALDH1A1 | |
| SCHEMBL26804140 | 0.86 | SLC6A3 (0.72) | SLC6A3CASRALDH1A1 | |
| SCHEMBL26804115 | 0.83 | SLC6A3 (0.82) | SLC6A3CASR | |
| SCHEMBL26804129 | 0.83 | SLC6A3 (0.71) | SLC6A3FOLH1ALDH1A1 | |
| SCHEMBL26804107 | 0.81 | SLC6A3 (0.82) | SLC6A3CASRFOLH1 | |
| SCHEMBL21682973 | 0.81 | SLC6A3 (1.00) | SLC6A3CASRFOLH1 | |
| SCHEMBL21682977 | 0.80 | SLC6A3 (1.00) | SLC6A3CASRALDH1A1 | |
| SCHEMBL31471163 | 0.80 | SLC6A3 (1.00) | SLC6A3CASRALDH1A1 | |
| SCHEMBL23902831 | 0.80 | SLC6A3 (1.00) | SLC6A3CASR | |
| SCHEMBL26804098 | 0.78 | SLC6A3 (0.85) | SLC6A3CASRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | SLC6A3 2908/4885CASR 4362/4885FOLH1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.